Lucid Diagnostics Inc.: notice of Nasdaq minimum bid price deficiency

What happened

• The filing says the company received a notice on Oct 12, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC that, for the prior 30 consecutive business days through Oct 9, 2026, the closing bid price of the company’s common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
• The notice states the company would be afforded 180 calendar days (until Apr 12, 2027) to regain compliance by having a closing bid price of at least $1 for a minimum of ten consecutive business days. The notice also states the company may be eligible for an additional 180-day period if it does not regain compliance within the initial period.
• The notice has no effect at this time on the listing of the company’s common stock, which will continue to trade uninterrupted under the symbol “LUCD.” The filing says the company intends to consider all available options to regain compliance.

Key details

• Notice received: Oct 12, 2026. Deficiency period referenced: 30 consecutive business days through Oct 9, 2026.
• Nasdaq rule cited: Listing Rule 5550(a)(2), minimum closing bid price of $1 per share.
• Cure period: 180 calendar days (until Apr 12, 2027) to achieve a closing bid price of at least $1 for ten consecutive business days; possible additional 180-day extension.

Why it may matter

• This item is reported under Item 3.01: Notice of delisting or failure to satisfy a continued listing rule or standard, which covers Nasdaq notification of a minimum bid price deficiency and the related compliance cure periods. A filing does not show why the insider traded or why the company acted.